Skip to main content

When you suspect an invasive fungal infection (IFI), one day can be the difference between life and death.*

With a robust fungal menu, differential testing, faster result turnaround time and diagnostics to monitor drug levels, Eurofins Viracor can help you better support your patients' continuum of care — from the onset of symptoms to managing dosage.

* Fungal tests result the same day (within 8-12 hours) of specimen receipt.

Fungal Diagnostics Diagram

 

When Timing is Critical,
Can You Afford Not to Know?

Risks of Treatment Delay

Treat IFIs Faster, Reduce Mortality

Managing fungal infections in immunocompromised individuals can be challenging due to a lack of specific symptoms and increased drug resistance. A rapid and accurate diagnosis is key in reducing the risk of mortality due to delayed treatment.1,2 

Utilizing Therapeutic Drug Monitoring

Manage Drug Levels, Keep Patients in the Therapeutic Range

For high-risk IFI patients, early individualized treatment is critical. Antifungal therapeutic drug monitoring is necessary for managing efficacy and safety.

The below chart shows the relationship between voriconazole dosage and blood levels.
In this study, up to 35% of patients samples were outside the therapeutic range.3

 

Diagnostics for Fungal Patients' Complete Continuum of Care

With testing that aids in differential diagnosis, faster treatment and drug level monitoring, your patient will do better and the hospital can lower costs.

Depend on Eurofins Viracor for clinical testing and rapid turnaround time that make a difference for everyone.

Fungals Infographic

Fungal Posters

Mucor

Invasive Mucormycosis Management: Mucorales PCR Provides Important, Novel Diagnostic Information

In immunocompromised patients, high mortality and morbidity of invasive mucormycosis (IM) remain significant healthcare issues due in part to confusion of IM with invasive aspergillosis (IA) and failure to initiate appropriate therapy. A validated Mucorales (MUC) PCR detects the causative agents of IM with good sensitivity and specificity, as reported previously (M-227, ICAAC 2013). Published studies have not definitively determined the frequency of patients for whom pulmonary IA is suspected but IM is present. We aimed to (1) estimate the frequency of MUC PCR positivity in bronchoalveolar lavage (BAL) samples submitted for Aspergillus (ASP) PCR panel testing.

VIEW POSTER

Nocardia

Addressing Pulmonary Nocardiosis Risk In Immunocompromised Patients: Development and Validation of a Commercially Available PCR

Pulmonary nocardiosis is an infection targeting immunocompromised patients characterized by high mortality and requires non-frontline antibiotics for treatment. Nocardiosis is currently confirmed or excluded by BAL fluid culture followed by further phenotypic identification steps. A culture-independent method with more timely results would accelerate the administration of appropriate treatment. A rapid Nocardia (NOC) PCR assay for BAL has neither been previously validated nor offered for clinical testing to our knowledge.

VIEW POSTER

Aspergillus

A Reproducible, Scalable Method For Detection of Aspergillus From Formalin-Fixed Parafin Embedded (FFPE) Tissue Samples

Invasive fungal infections are a serious concern for immunocompromised patients.  Aspergillus is a common fungal pathogen among both solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) that has a mortality rate of 35-59% in these populations2,3.  Early diagnosis is important to determine the proper antifungal treatment and reduce mortality.

VIEW POSTER

Explore our Fungal Test Menu

Test Name

Test Code

Turnaround Time

Fungal Plus PCR Profile I
Aspergillus • Nocardia • Mucorales

PFL8005

Same day (within 12 - 24 hours from receipt of specimen), Monday through Friday.

Fungal Plus PCR Profile II
Aspergillus • Nocardia • Mucorales • Pneumocystis jiroveci

PFL8006

Fungitell® β-D-Glucan

1700

Fungitell® β-D-Glucan with Reflex to Titer

351700

Same day (within 8-12 hours from receipt of specimen), Monday through Saturday. Additional 8-24 hours when reflex testing is required.

Aspergillus Real-time PCR Panel

8900

 
Candida Real-time PCR Panel

33306

Same day (within 12 - 24 hours from receipt of specimen), Monday through Friday.

Candida auris Real-time PCR (axilla/groin or nares)

33330

Same day (within 12 - 24 hours from receipt of specimen), Monday through Friday.

OMEGA Coccidioides Antibody EIA

3400

3 days from sample receipt. Testing performed at VRL-Eurofins.

Aspergillus Galactomannan EIA

1600

Same day (within 8 - 12 hours from receipt of specimen), Monday through Saturday.

Histoplasma Galactomannan EIA

30881/30882/33222/33251

Same day (within 8 - 18 hours from receipt of specimen), Monday through Saturday.

Mucorales Real-time PCR

3200

Same day (within 12 - 24 hours from receipt of specimen), Monday through Friday.

Nocardia Real-time PCR

6800

Same day (within 8-12 hours from receipt of specimen), Monday through Saturday.

Pneumocystis jiroveci Quantitative Real-time PCR

2000

Isavuconazole (CRESEMBA®) LC-MS/MS

4900

Itraconazole LC-MS/MS

2800

Posaconazole LC-MS/MS

4200

Voriconazole LC-MS/MS

3300

Let's Get You Started

Set Up An Account

We want to be your clinical lab partner.

When you work with us, you're accessing over 35 years of diagnostic innovation and specialized expertise in infectious disease, pre- and post-transplant, allergy and immunology testing for immunocompromised and critical patients.
Let's get started!

 

References

1 Assoc of Cape Cod, Fungitell Assay Instructions for Use. 2011 (Feb) Garey et al, Clin Infect Dis. 2006; 43:25-31. Karageorgopoulos et al. Clin Inf Dis. 2011; 52:750-770

2 Luong ML et al. Clin Inf Dis. 2012; 52 (10):1218-1226. Nguyen ML, Wissel MC et al. Clin Inf Dis. 2012; 54:1240-1248.

3 Andres Pascual, Thierry Calandra, Saskia Bolay, Thierry Buclin, Jacques Bille, and Oscar Marchetti, Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes, Clinical Infectious Diseases, 2008:46(2);204 by permission of Infectious Diseases Society of America.

Back to top